Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
Top Cited Papers
- 1 October 2000
- journal article
- clinical trial
- Published by Springer Nature in Nature Medicine
- Vol. 6 (10) , 1176-1182
- https://doi.org/10.1038/80525
Abstract
In this ‘double-blind’, randomized, placebo-controlled phase II trial, we compared an altered peptide ligand of myelin basic protein with placebo, evaluating their safety and influence on magnetic resonance imaging in relapsing–remitting multiple sclerosis. A safety board suspended the trial because of hypersensitivity reactions in 9% of the patients. There were no increases in either clinical relapses or in new enhancing lesions in any patient, even those with hypersensitivity reactions. Secondary analysis of those patients completing the study showed that the volume and number of enhancing lesions were reduced at a dose of 5 mg. There was also a regulatory type 2 T helper-cell response to altered peptide ligand that cross-reacted with the native peptide.Keywords
This publication has 37 references indexed in Scilit:
- A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complexNature Genetics, 1996
- A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22Nature Genetics, 1996
- Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous SystemCell, 1996
- Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic proteinNature, 1996
- Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligandImmunity, 1995
- Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production.The Journal of Experimental Medicine, 1994
- Immunological Aspects of Demyelinating DiseasesAnnual Review of Immunology, 1992
- T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosisNature, 1990
- Multiple sclerosis: Involvement of interferons in lesion pathogenesisAnnals of Neurology, 1988